Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Mesothelioma 3Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 11Pemetrexed 8Paclitaxel 8Radiotherapy 7Docetaxel 7Bevacizumab 7Cisplatin 6Gemcitabine 5pembrolizumab 3Taxes 3Metformin 3Vinorelbine 2Thalidomide 2Radiotherapy, Conformal 2Nivolumab 2Cetuximab 2trametinib 1sintilimab 1satraplatin 1ribociclib 1pegfilgrastim 1naporafenib 1motexafin gadolinium 1milademetan 1cixutumumab 1atezolizumab 1anetumab ravtansine 1aldesleukin 1Watchful Waiting 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma of Lung × LMB-100 × Clear all
NCT04027946 2024-04-16

LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
6 enrolled 14 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡